In a move signaling a major escalation in the Trump administration’s efforts to reshape the American healthcare landscape, the Centers for Medicare & Medicaid Services (CMS) released a sweeping proposed rule on Thursday. The 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) rule aims to drastically alter how Medicare compensates healthcare providers, focusing heavily on drug pricing reform and the reduction of cost disparities between hospital-based outpatient departments and independent clinics.
The proposed regulations, which represent a significant pillar of the administration’s broader agenda to curb rising healthcare expenditures, have ignited a firestorm of debate between federal regulators and the hospital industry. By targeting the long-standing 340B drug discount program and expanding "site-neutral" payment policies, the CMS is aiming to capture billions in federal savings while placing the onus of cost-containment on providers.
The Core of the Proposal: Reining in 340B and Site-Neutrality
At the heart of the proposed rule is a dual-pronged strategy: aggressive reform of the 340B drug program and the broadening of site-neutral payment policies. The 340B program, established decades ago to assist hospitals serving vulnerable populations in purchasing outpatient drugs at a discount, has long been a target for fiscal hawks. Regulators argue that the current structure of the program allows hospitals to receive Medicare reimbursements that far exceed their actual acquisition costs, effectively creating a profit margin on top of taxpayer-funded services.
CMS Administrator Dr. Mehmet Oz framed the proposal as a necessary corrective measure for patient affordability. "This proposed rule focuses squarely on patient affordability by strengthening our utilization management tools, aligning drug payments with actual acquisition costs, and removing site-of-care disparities that have unnecessarily driven up costs for millions of seniors," Dr. Oz stated in a press release accompanying the announcement.
Under the new proposal, Medicare would shift its reimbursement strategy for 340B drugs. Currently, Medicare pays for Part B drugs at the average sales price (ASP) plus 6%. The new rule proposes to reimburse hospitals at the drug’s ASP minus 33.4%. Medicare officials estimate this change alone would reduce total drug spending by $5.7 billion in 2027, including $1.15 billion in reduced out-of-pocket costs for Medicare beneficiaries.
A Chronology of Conflict: The Legal Battle Over 340B
The tension between the federal government and hospital systems over 340B reform is not new; it is a multi-year saga of regulatory attempts and judicial intervention.
The administration’s current proposal is the latest in a series of attempts to tighten the purse strings on 340B. In 2017, the CMS attempted to finalize a policy that would have reimbursed 340B drugs at ASP minus 22.5%. That effort was met with immediate legal resistance, culminating in a 2022 Supreme Court ruling that struck down the policy. The Court determined the CMS had acted unlawfully by failing to conduct a formal study of relevant hospitals’ drug acquisition costs before implementing the pay cuts.
This judicial rebuke forced the federal government to backtrack, resulting in years of back-pay to hospitals that had been under-reimbursed during the interim. This year, however, the CMS believes it has fortified its position. Regulators assert that they have completed a comprehensive survey of outpatient drug pricing, revealing "significant disparities" between 340B acquisition costs and market-rate pricing. CMS officials claim this survey provides the legal foundation that was missing in 2017, though legal experts anticipate that the new 340B policy will face fresh litigation from industry groups.
Supporting Data and Financial Implications
The financial impact of the 2027 OPPS rule is significant, as the policy must remain "budget neutral." Because the savings generated from the 340B cuts must be redistributed, the CMS proposes to increase outpatient payments for non-drug services by an equivalent amount.
According to a research note from TD Cowen, this structure creates a distinct financial divide. Non-340B providers—including many for-profit hospital systems—stand to be the "major beneficiaries" of this redistribution, as their non-drug service reimbursements will rise while they remain insulated from the cuts applied to the drug discount program.
Beyond 340B, the broadening of site-neutral payments for imaging services represents another significant fiscal pivot. Currently, Medicare pays higher rates for procedures conducted in hospital-owned outpatient departments compared to the same procedures performed in independent physician offices or ambulatory surgery centers. The CMS argues this disparity incentivizes unnecessary hospital consolidation and creates a financial burden for patients. By equalizing payments for imaging services without contrast, the agency expects to reduce Medicare Part B expenditures by approximately $260 million in the first year.
Official Responses: A Deep Divide
The reaction to the proposal has been starkly polarized. While the CMS and administration officials champion the rule as a victory for transparency and fiscal responsibility, hospital advocacy groups are sounding the alarm.
Jennifer DeCubellis, President and CEO of America’s Essential Hospitals, issued a sharp critique, arguing that the policy ignores the reality of the healthcare delivery system. "The proposed OPPS rule from CMS takes an axe to critical funding that supports essential hospitals without concern for how it will affect the patients they serve," DeCubellis said. She and other industry advocates contend that the 340B discounts are not "windfalls" but essential resources that allow safety-net providers to keep their doors open and provide care to underserved populations.
Conversely, the CMS maintains that the current system incentivizes inefficiency. The agency points to instances where beneficiary cost-sharing—based on the inflated Medicare payment rate—actually exceeds the total price the hospital paid to acquire the drug through 340B. For the administration, this represents a systemic flaw that harms seniors and inflates the federal deficit.
Broadening the Scope: Transparency, Botox, and Oversight
While the 340B and site-neutral provisions dominate the headlines, the 2027 rule contains several other notable regulatory changes:
- Price Transparency: The CMS has issued a Request for Information (RFI) regarding hospital price transparency. Despite mandates that have been in place since 2021, the agency notes that compliance remains uneven. Many hospitals have moved away from publishing actual dollar-amount pricing, instead opting for complex algorithms or estimated percentages that hinder consumer choice. The RFI seeks to standardize these reporting requirements to make data more "consumer-friendly."
- Prior Authorization for Botox: The agency is targeting the rising volume of botulinum toxin (Botox) injections. Citing a lack of clinical justification for the surge in usage, the CMS is proposing to add eight new injection codes to the list of procedures requiring prior authorization.
- EMTALA Oversight: In an effort to streamline operations, the CMS proposes allowing certain hospital accrediting organizations to assess compliance with the Emergency Medical Treatment and Labor Act (EMTALA). By giving these organizations the power to conduct inspections, the CMS hopes to reduce duplicative state-level investigations and minimize operational disruptions for hospitals.
- Inpatient-Only List: The agency continues its phase-out of the "inpatient-only" list, which dictates which procedures must be performed in a hospital setting. The 2027 rule targets an additional 638 services for removal, furthering the shift toward outpatient surgery.
Implications for the Future of Healthcare
The 2027 OPPS proposed rule is more than a simple adjustment of payment rates; it is a manifestation of the current administration’s philosophy on market-driven healthcare. By attempting to force convergence between hospital-based and independent clinic pricing, and by aggressively auditing the 340B program, the government is signaling that it is willing to challenge the traditional business models of large hospital systems.
For hospitals, the coming months will be a period of intensive lobbying and legal maneuvering. The industry is expected to file significant comments during the public feedback window, arguing that the proposed cuts will jeopardize patient access to specialized care.
For the CMS, the goal is clear: to bend the cost curve of Medicare by ensuring that federal dollars are directed toward "clinically appropriate" care rather than administrative overhead or arbitrage. As the rule moves through the public comment process, the ultimate impact will depend on whether the administration can withstand the inevitable legal challenges and whether the projected savings can be realized without triggering the instability that critics fear.
As of now, the healthcare sector is bracing for a potential transformation. If finalized as written, the 2027 OPPS rule will rewrite the financial incentives for hospitals, forcing a re-evaluation of how they purchase drugs, price their services, and provide care to the most vulnerable members of the population.
